A clinical trial of LY01013

Trial Profile

A clinical trial of LY01013

Planning
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs LY-01013 (Primary)
  • Indications Bladder cancer; Head and neck cancer; Lung cancer; Malignant melanoma; Renal cancer; Skin cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Mar 2018 New trial record
    • 26 Jan 2018 According to a Luye Pharma Group media release, clinical trial application for LY01013 is accepted by the China Food and Drug Administration (CFDA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top